Related Experiment Video
Updated: Oct 5, 2025
Inducing Meningococcal Meningitis Serogroup C in Mice via Intracisternal Delivery
Published on: November 5, 2019
Real-world implementation of 4-component meningococcal serogroup B vaccine (4CMenB): implications for clinical
Woo-Yun Sohn1, Halima Tahrat1, Patricia Novy2
1GSK, Rockville, MD, USA.
Introduction:
Invasive meningococcal disease due to serogroup B (MenB) is an uncommon but life-threatening disease. The 4-component meningococcal serogroup B vaccine (4CMenB) is the only MenB vaccine with real-world evidence supporting a reduction in incidence without safety concerns.
Areas Covered:
We reviewed recommendations and real-world implementation of 4CMenB in National Immunization Programs (NIPs) and implications for clinical practice through a non-systematic literature search.
Expert Opinion:
4CMenB is registered in 45 countries, 33 of which recommend it clinically: nine for infants, children, adolescents, and high-risk groups; 11 for infants and high-risk groups; the US for individuals aged 16-23 years and high-risk groups; two for infants; 10 for high-risk groups and/or outbreak control. Dosing schedule varies between countries. To date, nine countries include 4CMenB in their NIP: UK, Andorra, Ireland, Italy, San Marino, Lithuania, Malta, Czech Republic, and Portugal. Australia funds it for Aboriginal and Torres Strait Islander children under 2 years, and high-risk individuals. South Australia funds for all infants and adolescents. Many factors influenced introduction into NIPs: disease burden, public awareness, cost-effectiveness, prior meningococcal vaccination programs, efficacy and safety profile. In the future, more countries might consider including 4CMenB in their NIP due to growing evidence on effectiveness and safety.
Insights
The 4-component meningococcal serogroup B vaccine (4CMenB) is recommended in 33 countries, with nine including it in national immunization programs. Growing evidence supports its effectiveness and safety for broader adoption.
Area of Science:
- Vaccinology
- Public Health
- Epidemiology
Background:
- Invasive meningococcal disease caused by serogroup B (MenB) is a rare but severe illness.
- The 4-component meningococcal serogroup B vaccine (4CMenB) is the sole MenB vaccine with documented real-world efficacy and a favorable safety profile.
Purpose of the Study:
- To review the global recommendations and implementation of the 4-component meningococcal serogroup B vaccine (4CMenB) in National Immunization Programs (NIPs).
- To assess the implications of 4CMenB's real-world use for clinical practice and future public health strategies.
Main Methods:
- A non-systematic literature search was conducted.
- Recommendations and real-world implementation data for 4CMenB in NIPs were reviewed.
Main Results:
- The 4-component meningococcal serogroup B vaccine (4CMenB) is registered in 45 countries and clinically recommended in 33.
- Nine countries have incorporated 4CMenB into their National Immunization Programs, with varying dosing schedules.
- Factors influencing NIP inclusion include disease burden, cost-effectiveness, and vaccine profile; broader future adoption is anticipated.
Conclusions:
- The 4-component meningococcal serogroup B vaccine (4CMenB) demonstrates significant clinical recommendations and growing NIP inclusion globally.
- Evidence of effectiveness and safety is driving increased consideration for 4CMenB integration into national vaccination strategies.
- Continued monitoring of real-world data will be crucial for informing future public health decisions regarding MenB vaccination.
